Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma

NCT06903273 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma
Biliary Tract Cancer (BTC)

Interventions

DRUG: Tislelizumab

Sponsor

National Cheng-Kung University Hospital

Collaborators

[object Object]
[object Object]